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Abstract 
Background: Achieving undetectable viral load is crucial for the reduction of HIV transmissions, AIDS-related ill-
nesses and death. Adolescents (10 to19 years) living with HIV (ALHIV) on antiretroviral treatment (ART) have worse 
treatment adherence and lower viral suppression rates compared to adults. We report on the clinical factors associ-
ated with viral suppression among ALHIV in the Ehlanzeni district, Mpumalanga in South Africa.
Methods: A cross-sectional analysis was conducted with 9386 ALHIV, aged 10 to 19 years, who were enrolled in 136 
ART clinics in the Ehlanzeni district. Clinical and immunological data were obtained from electronic medical records 
(Tier.net). ALHIV were categorised as having achieved viral suppression if their latest viral load count was < 1000 
ribonucleic acid (RNA) copies/mL. Using a backward stepwise approach, a multivariate logistic regression analysis was 
performed to identify factors independently associated with viral suppression.
Results: The mean age of the participants was 14.75 years (SD = 2.9), and 55.43% were female. Mean duration 
on ART was 72.26 (SD = 42.3) months. Of the 9386 adolescents with viral load results recorded, 74% had achieved 
viral suppression. After adjusting for other covariates, the likelihood of achieving viral suppression remained signifi-
cantly higher among ALHIV who were: female (AOR = 1.21, 95% CI 1.05–1.39), and had most recent CD4 count > 200 
(AOR = 2.53, 95% CI 2.06–3.11). Furthermore, the likelihood of having viral suppression was lower among adolescents 
with CD4 count > 200 at baseline (AOR = 0.73, 95% CI 0.61–0.87), and who were switched to second line regimen 
(AOR = 0.41, 95% CI 0.34–0.49).
Conclusions: Viral suppression amongst ALHIV at 74% is considerably lower than the WHO target of 95%. Of par-
ticular concern for intervention is the lower rates of viral suppression amongst male ALHIV. Greater emphasis should 
be placed to early enrolment of ALHIV on ART and keeping them engaged in care (beyond 6 months). Furthermore, 
improved and regular viral load monitoring will help to adequately identify and manage ALHIV with unsuppressed 
viral load and subsequently switching to second line treatment.
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Introduction
In 2018, UNAIDS estimated that 1.6 million young 
people aged 10  to  24  years were living with HIV [1, 2]. 
Therefore, young people living with HIV constitute a 
growing and key sub-population of people living with 
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HIV globally. The increase in HIV prevalence amongst 
adolescents (10  to  19  years) is the result of the genera-
tion of children infected with HIV perinatally who are 
surviving into adolescence because of improved access 
to antiretroviral treatment (ART), and increased HIV 
incidence as a result of risky (sexual) behaviour in this 
age group [3, 4]. Despite tremendous gains in the reduc-
tion of over-all AIDS-related deaths to the tune of 43%, 
AIDS-related deaths amongst adolescents in Eastern and 
Southern Africa have increased in the last decade [5]. 
This is mainly because adolescents struggle to initiate and 
remain engaged on antiretroviral treatment (ART) [6].
Monitoring the level of detectable viral load and 
achieving undetectable viral loads are crucial in the 
reduction of HIV transmission, earlier detection of treat-
ment failure, and timely switching to second-line ART 
[7–10]. The aim of ART is to suppress the replication of 
the HIV thereby protecting people living with HIV from 
AIDS-related illnesses and death and preventing further 
transmission to others [3, 11]. Conversely, adolescents 
who have poor ART adherence are at greater risk of mor-
bidity, mortality, treatment failure, the development of 
drug resistant forms of HIV, viral progression, oppor-
tunistic infections, and transmission to babies and sexual 
partners [8, 12–16].
Compared to adult populations living with HIV, adoles-
cents living with HIV (ALHIV) have a higher likelihood 
of suboptimal adherence, viral load progression, lost to 
follow-up, morbidity and mortality [11, 17, 18]. This is 
because adolescence is accompanied by rapid physical, 
psychological and physiological changes, which influence 
health‐related behaviour [19]. Therefore, monitoring the 
treatment outcomes for ALHIV is crucial as they become 
aware of their HIV status and have to navigate health 
care facilities and self-manage their medication adher-
ence and retention in ART care [20]. Regrettably, there is 
limited information on viral outcomes of adolescents in 
sub-Saharan Africa where the biggest burden of deaths is 
experienced, because these results are masked by routine 
reporting for children under 14  years and adults from 
15 years up only [17, 19].
The aim of this study is to investigate the predictors 
of viral load suppression among HIV-positive adoles-
cents (10  to  19  years) receiving ART in the Ehlanzeni 
district of South Africa. Improved reporting of virologi-
cal outcomes from a wider range of settings is required 
to support efforts to improve HIV care and treatment for 
adolescents [19].
Setting
Ehlanzeni District municipality is in Mpumalanga prov-
ince, located in the Northern Eastern part covering the 
whole Southern part of the Kruger National Park. The 
district is surrounded by Mozambique in the East and 
Swaziland in the South. The district comprises of four 
sub-districts namely: Bushbuckridge, City of Mbombela, 
Nkomazi, and Thaba Chweu.
According to the 2017 South African National HIV 
prevalence, incidence, behaviour and communication 
survey, among people living with HIV in South Africa, 
Mpumalanga province has the second highest HIV prev-
alence with an estimated prevalence rate of 17.3%, and 
the lowest in viral load suppression (82.9%) [21, 22]. Fur-
thermore, the Ehlanzeni district compared to other dis-
tricts has high rate of people living with HIV who know 
their HIV status  (1st 95), 90.6%. On the contrary, ART 
coverage  (2nd 95) remains low at 67.2%, and lowest rate of 
viral load suppression at 65.3% [21].
Methods
Study design and participants
A cross-sectional analysis of routine data on ALHIV, aged 
10 to 19 years, who were registered to receive ART from 
136 clinics in the Ehlanzeni district between September 
2002 and October 2019 was conducted. On October 31, 
2019, we extracted  anonymized individual patient data 
(sociodemographic variables), clinical data and treat-
ment outcomes (viral load result) of ALHIV who have 
been on ART for at least 6 months from electronic medi-
cal records (TIER.net) as part of a larger study assessing 
the effects of psychosocial support on adherence, treat-
ment outcomes (viral suppression) and retention in care 
amongst adolescents on ART. The Tier.net electronic 
record only records the last viral load test done; CD4 
count at baseline and most recent CD4 count.
ALHIV who have been on ART for less than 6 months, 
without viral load done, who have died, lost to follow-up, 
and transferred/moved out were excluded from the anal-
ysis. Only ALHIV with viral load done after 6 months of 
ART initiation were included in the analysis (see Addi-
tional file  1: Appendix S1 for inclusion and exclusion 
criteria).
The primary outcome, viral suppression, was defined 
according to the South African National Department 
of Health as patients achieving a viral load < 1000 RNA 
copies/mL [23]. In South Africa, the first viral load test 
is done 6 months after initiation on ART. The predictor 
variables such as age, gender, method of entry into ART 
programme at the health facility, pregnant on ART, age 
at ART initiation, duration on ART, initiated on Isonia-
zid Preventive Therapy (IPT), TB history,  CD4 count 
at baseline and last ART visit (most recent CD4 count), 
WHO stage at initiation, and initiated on ART same day 
as HIV diagnosis were employed in a bivariate and mul-
tivariate analysis to determine factors influencing viral 
suppression.
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Analysis
Data were extracted from the Tier.Net medical elec-
tronic record in Excel, and imported to STATA statisti-
cal software version 16.0 (STATA Corporation, College 
Station, Texas, USA) for analyses. Information on clini-
cal stationery was reviewed against information on Tier.
net. Patient clinical records identified as incomplete or 
not correctly captured on Tier.net was retrieved and 
subsequently updated on Tier.Net.
Descriptive statistics were used to characterize the 
demographic and clinical variables (at baseline and/
or   six months after ART initiation). Comparisons 
between viral suppression and clinical parameters 
among adolescent living with HIV were achieved using 
chi-square tests for proportions (replaced by Fish-
er’s exact test for sparse data), and bivariate logistics 
regression analysis to examine associations.
Furthermore, a multivariate logistic regression model 
was used to estimate factors associated with viral sup-
pression adjusting for potential confounders using the 
following variables: age, gender, age at ART initiation, 
duration on ART, CD4 cell count at baseline and most 
recent CD4 cell count, WHO stage at initiation, and 
initiated on ART same day as HIV diagnosis. The multi-
variate logistic regression model employed a backward 
stepwise analysis. In the backward selection model, 
we included all candidate variables in the model with 
p < 0.15 in selecting the final model [24]. At each step, 
the variable that is the least significant is removed. This 
process continued until no non-significant variables 
remained. The significance level was set at 95% at which 
variables can be removed from the model. Analyses 
were conducted among all patients with viral load test 
done after 6 months of ART initiation.
Ethics approval
Ethics clearance was obtained from the University of 
the Western Cape Biomedical Research Ethics com-
mittee (BM19/1/8) and informed consent to use the 
Tier.Net medical electronic dataset was obtained 
from the National Health Research Ethics commit-
tee  (MP_202102_006). We adhered to the 1964 dec-
laration of Helsinki guidelines. According to the 
declaration, research that involves human subjects 
amongst others must keep with the following (1) strive 
to protect life, health, privacy, and the dignity of the 
research participants, (2) employ greater care to pro-
tect the participants from harm and (3) conduct the 
research because the importance of the research pur-
pose, outweighs the risk that might be attributed to 
the study either at present or in the future (18th WMA 
General Assembly, Helsinki, 2001).
Data extraction excluded adolescent’s unique identi-
fiers such as name, surname, patient folder number and 
identity number.
Results
Table 1 shows the demographic characteristics of ALHIV 
enrolled in the ART programme in 136 facilities in 
Ehlanzeni district South Africa. This study included 
9386 adolescents (aged 10 to 19  years) with mean age 
14.75 years (SD = 2.9); of whom 55.43% were female. Of 
the 9386 ALHIV with viral load results recorded, 74.31% 
had achieved viral suppression. Compared to ALHIV in 
the age group (15 to 19 years), ALHIV (10 to 14 years) are 
more likely to have viral load below 1000 RNA copies/mL 
(p < 0.001).
In terms of gender comparison, females are more 
likely to have viral load below 1000 RNA copies/mL 
(p = 0.000). Most (67.88%) of the ALHIV attended the 
ART programme in the clinic they were initiated as new 
patients as opposed to transferred in from another clinic. 
Amongst the female ALHIV, 8.35% were reported preg-
nant at the time of enrolling into ART.
Demographic and clinical history
Table 1 shows the clinical history of ALHIV enrolled in 
the ART programme in Ehlanzeni district South Africa. 
The mean age at which the adolescents started ART was 
8.7 years (SD = 4.8); and 85.44% were on ART for more 
than 25 months. ALHIV on ART for six to eleven months 
were more likely to attain viral suppression compared to 
adolescents on ART for 12 to 17 months and 25 months 
and above (p = 0.002).
Only 22.49% (n = 2111) were started on Isoniazid pre-
ventative therapy (IPT) after ART initiation. Only 2.6% 
completed TB preventive therapy.  ALHIV who were 
started on IPT after ART initiation were more likely to 
attain viral suppression compared to those who did not 
(p = 0.002).
Regarding history of TB, 0.87% had a TB and HIV 
comorbidity. ALHIV with a history of TB were less likely 
to have viral load < 1000 RNA copies/mL (p = 0.009).
Compared to ALHIV with CD4 count > 200, ALHIV 
with CD4 count < 200 were less likely to have viral 
load < 1000 RNA copies/mL (p < 0.001). This is true for 
CD4 count at baseline and CD4 count at last visit or most 
recent CD4 count.
Slightly more than half (52.72%) of the ALHIV 
were initiated on ART at WHO stage 1. Compared to 
ALHIV with WHO stage 1, 2, and 3 at ART initiation, 
ALHIV with WHO stage 4 were less likely to have viral 
load < 1000 RNA copies/mL (p < 0.001).
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Table 1 Viral load suppression by demographic and clinical characteristics of adolescents 10 to 19 years living with HIV in Ehlanzeni 
district, South Africa (N = 9386)








Current age (in years) 0.000
 10 to 14 4506 (48.01) 3455 (76.41) 1063 (23.59)
 15 to 19 4880 (51.99) 3603 (72.38) 1348 (27.62)
Gender 0.000
 Female 5158 (54.95) 3946 (76.50) 1212 (23.50)
 Male 4253 (44.57) 3029 (71.64) 1199 (28.36)
Pregnant at ART start (N = 5160) 0.001
 No 4729 (91.65) 3590 (75.91) 1139 (24.09)
 Yes 431 (8.35) 357 (82.83) 74 (17.17)
Age at ART start (in years) 0.000
 0 to 9 5512 (58.73) 4116 (74.67) 1396 (25.33)
 10 to 14 2548 (27.15) 1786 (70.09) 762 (29.91)
15 to 19 1326 (14.13) 1073 (80.92) 253 (19.08)
Duration on ART (in months) 0.002
 6 to 11 months 459 (4.89) 364 (79.30) 95 (20.70)
 12 to 17 months 450 (4.79) 332 (73.78) 118 (26.22)
 18 to 24 months 458 (4.88) 366 (79.91) 92 (20.09)
 25 months + 8019 (85.44) 5913 (73.74) 2106 (26.26)
Initiated on Isoniazid Preventative Therapy (IPT) 0.002
 Yes 2111 (22.49) 1623 (76.88) 488 (23.12)
 No 7,275 (77.51) 5352 (73.57) 1923 (26.43)
History of TB 0.009
 Yes 78 (0.87%) 48 (61.54%) 30 (38.46%)
 No 8934 (99.13%) 6659 (74.54%) 2275 (25.46%)
CD4 count at last ART visit (n = 7999)
 < 200 1071 (13.39%) 608 (56.77%) 463 (43.23%) 0.000
 > 200 6928 (86.61%) 5284 (76.27%) 1644 (23.73%)
CD4 count at baseline 0.006
 CD4 < 200 1676 (28.16%) 1200 (71.60%) 476 (28.40%)
 CD4 > 200 4276 (71.84%) 3210 (75.07%) 1066 (24.93%)
WHO stage at initiation 0.000
 1 4067 (52.72%) 3106 (76.37%) 961 (23.63%)
 2 1873 (24.28%) 1363 (72.77%) 510 (27.23%)
 3 1527 (19.79%) 1088 (71.24%) 439 (28.75%)
 4 248 (3.21%) 176 (70.97%) 72 (29.03%)
Initiated same day 0.145
 Yes 808 (61.59%) 631 (78.09%) 177 (21.91%)
 No 504 (38.41%) 376 (74.60%) 128 (25.40%)
Initiated on second line ART 
 Yes 1550 (16.51%) 888 (57.29%) 662 (42.71%) 0.000
 No 7836 (83.49%) 6087 (77.68%) 1749 (22.32%)
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Table 2 Multivariate logistic regression analysis of factors associated with viral suppression among adolescents living with HIV in 
Ehlanzeni district South Africa (N = 9386)
* p-value statistically significant at 5%
Crude OR 95% CI Adjusted OR 95% CI
Age
 10 to 14 1* 0.74–0.89 1
 15 to 19 0.81 0.92 0.78–1.09
Gender
 Male 1* 1.17–1.41 1*
 Female 1.29 1.21 1.05–1.39
Method into ART at facility
 Transferred in from another facility 1
 New ART patient 0.94 0.85–1.04
Started IPT
 No 1* 1
 Yes 1.19 1.01–1.25 1.04 0.89–1.23
History of TB
 No 1* 1
 Yes 0.55 0.35–0.86 0.73 0.37–1.26
WHO stage
 Stage 1 1* 1
 Stage 2 0.83 0.73–0.94 0.88 0.75–1.04
 Stage 3 0.77 0.67–0.91 0.86 0.72–1.03
 Stage 4 0.76 0.57–1.00 0.85 0.57–1.26
ART initiation on same day
 No 1
 Yes 1.21 0.93–1.57
Duration on ART 
 6 to 11 months 1* 1*
 12 to 17 months 0.73 0.54–0.99 0.62 0.25–1.55
 18 to 24 months 1.04 0.75–1.43 0.37 0.15–0.93
 25 months + 0.73 0.58- 0.92 0.60 0.22–1.28
Age at art start
 0 to 9 years 1* 1
 10 to 14 years 0.79 0.72–0.87 0.88 0.74–1.04
 15 to 19 years 1.44 1.24–1.67 1.30 0.97–1.75
Pregnant during ART start
 No 1*
 Yes 1.53 1.18–1.98
CD4 count at last visit
 CD4 < 200 1* 1*
 CD4 > 200 2.45 2.14–2.79 2.53 2.06–3.11
CD4 count at baseline
 CD4 < 200 1* 1*
 CD4 > 200 1.19 1.05–1.36 0.73 0.61–0.87
Second line
 No 1* 1*
 Yes 0.38 0.34–0.43 0.41 0.34–0.49
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Most (61.59%) of the ALHIV were initiated on ART on 
the same day of HIV diagnosis. However, there was no 
association between ALHIV’s time of ART initiation with 
viral load suppression (p = 0.145).
Only 16.51% (n = 1550) of ALHIV were switched to 
second line ART regimen. However, ALHIV who were 
switched to second line regimen were less likely to attain 
viral suppression (p < 0.001).
Factors associated with suppression of viral load 
among adolescent living with HIV (N = 9386)
Table 2 shows the factors associated with viral suppres-
sion in a multivariate logistic regression model. After 
controlling for the effect of other covariates, the likeli-
hood of attaining viral suppression remained signifi-
cantly higher among female adolescents (AOR = 1.21, 
95% CI 1.05–1.39), had most recent CD4 count > 200 
(AOR = 2.53, 95% CI 2.06–3.11). ALHIV on second line 
treatment were less likely to attain viral suppression 
compared to their reference group (AOR = 0.41, 95% CI 
0.34–0.49), followed by ALHIV who had been on ART 
for 18 to 24 months (AOR = 0.37, 95% CI 0.15–0.93), and 
ALHIV with CD4 count > 200 at baseline (AOR = 0.73, 
95% CI 0.61–0.87).
Discussion
In this study, we set out to investigate the predictors of 
viral load suppression among ALHIV receiving ART 
in the Ehlanzeni district of South Africa. The propor-
tion of ALHIV with viral suppression after six months 
of ART initiation was relatively high at 74.31% compared 
to another study conducted in South Africa [20], but 
falls short of the global target of 95%. Furthermore, our 
study revealed that being female, and having most recent 
CD4 count level > 200 were associated with viral suppres-
sion. On the other hand, being on ART for more than six 
months, as well as being on second line treatment are 
enhancing factors for viral non-suppression.
Evidence on the relationship between gender and viral 
load suppression is mixed. While one study showed that 
males were more likely to achieve viral load suppres-
sion compared to females [20], another study found that 
males are more likely to achieve viral non suppression 
[25]. However, we found that females were more likely to 
attain viral suppression compared to males. Adherence 
among males ALHIV is poor compared to females; males 
have poor treatment seeking behaviours [25] and as 
such to get males to test for HIV, link and retain them to 
ART care remains a challenge [26]. The poor treatment 
outcome reported among males have been attributed to 
strong gender norms and practices specifically the per-
ception of masculinity inherent within societies in South 
Africa. In addition, lack of male-friendly services inhibits 
males from seeking health care services [26–28].
The literature indicates that older age group or adults 
can achieve viral suppression because they are able to 
successfully take their ART medication regularly without 
supervision i.e. possess self-efficacy and self-competency 
on ART adherence [9]. Interestingly, our study did not 
show any significant difference between viral suppres-
sion among adolescents in the age group 10–14  years 
and 15–19  years. This is likely because if no support is 
provided, adolescents (10–19  years) are faced with psy-
chosocial challenges, lack self-efficacy and self-esteem, 
and are unable to self-manage themselves with regard 
to medication adherence [29]. However, a retrospec-
tive study conducted among adolescents registered in 
the Cape Metropole ART clinic in South Africa found 
younger adolescents (10–14  years) were more likely to 
achieve viral suppression compared to older adolescents 
(15–19  years). It was reported that the older adoles-
cents face adherence challenges as a result of transition-
ing from adolescence to adulthood in which they are 
expected to self-manage themselves with regard to medi-
cation adherence [20].
We also found that longer duration (18 to 24 months) 
on ART was a risk factor for viral non-suppression. 
This is contrary with evidence that patients on ART for 
shorter period are more likely to experience virological 
failure [9]. Our study findings is interesting given that 
patients who have been on treatment longer have more 
experience in managing their treatment [9]. Similar find-
ings were reported in a study, which reported that ado-
lescents who had been on ART between 6 and 12 months 
were more likely to have viral non-suppression (viral 
load > 400 RNA copies/mL) compared with those who 
had been on treatment for longer [9].
Immunological treatment failure refers to a CD4 cell 
count of < 100 cells/µL after 6  months of therapy [9]. 
According to the WHO guidelines, a decreasing CD4 cell 
count is considered a proxy marker for treatment failure 
when viral load monitoring is not available, and should 
trigger a switch in ART, particularly if the CD4 cell count 
is < 200 cells/µL [9]. Although the relationship between 
viral non-suppression and immunological responses, is 
not always consistent [9], our study found that adoles-
cents with CD4 cell count > 200 cells/µL at last ART visit 
were more likely to achieve virological suppression. How-
ever, the ability of CD4 counts to predict virologic failure 
is poor [11].
Studies have shown that delayed detection of treat-
ment failure may increase drug toxicity, which in turn 
lead to the accumulation of drug resistance-associated 
mutations, hence may result in increased morbidity 
and mortality [30]. On the contrary, a timely switching 
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to second-line ART after virological failure along with 
enhanced adherence counselling is a protective factor 
against viral progression and mortality [10]. However, we 
included ALHIV who were already initiated on second 
line ART to determine whether second-line ART would 
be a successful ‘rescue’ for viral suppression. Our find-
ings showed that adolescents on second-line treatment 
were less likely to attain viral suppression. It is possible 
that those on second line regimen could have a history of 
poor adherence behaviour that continues in spite of being 
on the ‘rescue’ regimen. There is also evidence that hav-
ing a history of treatment failure is a risk factor for viral 
suppression [17]. Furthermore, second-line regimens are 
more complex than first-line regimens, are often twice 
daily regimens and have more adverse side effect than 
first-line regimens hence impacting negatively on adher-
ence. Unfortunately, assessing HIV resistance among 
HIV naïve patients is challenged by cost and volume of 
HIV positive patients in South Africa.
Findings implications
Several implications arise from our findings. First, to 
achieve the 95% global target by 2030, there is a need to 
design an intervention (i.e. psychosocial support) aimed 
at ALHIV to improve self-efficacy and self-competency 
so that they are able to adhere to their ART medication. 
Adopting a combination of multiple approaches includ-
ing psychosocial support intervention may be necessary 
to improve adherence. For instance, providing social sup-
port and focusing on psychosocial needs of adolescents 
to bolster their self-esteem and self-efficacy will in turn 
improve their self-management regarding medication 
adherence and subsequently improve their treatment 
outcomes.
Timely and accurate identification of virological fail-
ure is crucial to avoid misclassification of non-suppres-
sion leading to switching to a second-line or third-line 
which are costly and can lead to viral non suppression. 
It is recommended that second line regimens especially 
for ALHIV are simplified and changed to once daily, and 
less toxic regimens which could improve adherence and 
in turn lead to viral load suppression. Furthermore, pro-
viding enhanced adherence counselling for ALHIV who 
are males, on second line regimen and being on ART for 
more than 18 months is very crucial.
Study limitations
This study has a number of limitations, which should be 
taken into account when interpreting the findings. First, 
adolescents who are eligible for viral load assessment but 
failed to have it done because they were lost to follow-up, 
died or transferred out, were not included, which could 
have resulted in overestimating the rate of viral load 
suppression. Second, as is the case for all cross-sectional 
studies, it is subject to other risk or confounding factors 
that may be present but were not measured. For exam-
ple, household income status, head of household, type of 
social support and psychosocial well-being. Third, as is 
the case for routine programme data which is exposed to 
data quality issues. We were not able to delineate which 
clients had low CD4 because they were early in treatment 
and been allowed to have a drop in CD4 before initiation, 
and those that had been doing well and now had a drop 
in CD4. Similarly, the type of ART regimen used for first- 
and second-line treatment were excluded from analysis 
due to poor data capturing. Finally, the Tier.Net medi-
cal electronic record only captures the last viral load test 
done, as a result, we were unable to measure two con-
secutive viral load test three months apart for those with 
VL > 50 RNA copies/mL making it challenging to explain 
what is going on for those who are not undetectable as 
recommended by World Health Organisation.
Conclusion
Viral suppression amongst adolescents at 74% is consid-
erably lower than the WHO target of 95%. Of particular 
concern for intervention is the lower rates of viral sup-
pression amongst male adolescents. Greater emphasis 
should be placed to enrol adolescents on ART earlier and 
keeping them engaged in care (beyond 6  months). Fur-
thermore, improved and regular viral load monitoring 
will help to adequately identify and manage ALHIV with 
unsuppressed viral load and subsequently switching to 
second line treatment.
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